Evidence map›Paper›PMID 30911678›Full record

ReviewCommunications biology2019

Bridging human chaperonopathies and microbial chaperonins.

Everly Conway de Macario, Masafumi Yohda, Alberto J L Macario, Frank T Robb

Open access · goldAbstract readReview
In one paragraph

Review in Communications biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. The Role ofInternational journal of molecular sciences · 2025
    Review
  2. Article
  3. Genomic Insights into Vector-Pathogen Adaptation inPathogens (Basel, Switzerland) · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 4 countries.

Everly Conway de Macario1Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore-Institute of Marine and Environmental Technology (IMET), Columbus Center, Baltimore, MD USA.ORCID 0000-0001-9689-8844
Masafumi Yohda2Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, Koganei, Tokyo Japan.ORCID 0000-0001-8307-9671
Alberto J L Macario1Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore-Institute of Marine and Environmental Technology (IMET), Columbus Center, Baltimore, MD USA.ORCID 0000-0002-6181-2876
Frank T Robb1Department of Microbiology and Immunology, School of Medicine, University of Maryland at Baltimore-Institute of Marine and Environmental Technology (IMET), Columbus Center, Baltimore, MD USA.ORCID 0000-0001-5833-6496
University of Maryland, Baltimore · USTokyo University of Agriculture and Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chaperonins are molecular chaperones that play critical physiological roles, but they can be pathogenic. Malfunctional chaperonins cause chaperonopathies of great interest within various medical specialties. Although the clinical-genetic aspects of many chaperonopathies are known, the molecular mechanisms causing chaperonin failure and tissue lesions are poorly understood. Progress is necessary to improve treatment, and experimental models that mimic the human situation provide a promising solution. We present two models: one prokaryotic (the archaeon

Indexed as

Disease SusceptibilityArchaeal ProteinsBacterial ProteinsChaperoninsEukaryotic CellsFungal ProteinsHumansMethanosarcinalesMolecular ChaperonesMutationProtein ConformationSulfolobalesArchaeal ProteinsBacterial ProteinsChaperoninsFungal ProteinsMolecular Chaperones

Identifiers

PMID30911678
PMCPMC6420498
OpenAlexW2921339739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.